Nucl Med Mol Imaging.  2018 Aug;52(4):247-253. 10.1007/s13139-018-0522-0.

Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer

Affiliations
  • 1Department of Nuclear Medicine, School of Medicine, Kyungpook National University, 680, Gukchaebosang-ro, Jung-gu, Daegu 41944, Republic of Korea. abc2000@knu.ac.kr
  • 2Department of Nuclear Medicine, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Republic of Korea.

Abstract

Radioactive iodine (RAI) therapy for differentiated thyroid cancer has been successfully used for more than 70 years. However, there is still plenty of controversy surrounding the use and doses of radioiodine. There is insufficient evidence to answer the questions. Recent American Thyroid Association (ATA) guidelines seem to favor low-dose RAI, based on recent clinical trials and meta-analyses. However, long-term follow-up data remains limited, and there are additional factors we should consider that might affect the efficacy of RAI therapy. Therefore, until sufficient data are available, it is necessary to remain cautious about determining RAI doses by considering multiple patient-specific variables.

Keyword

Differentiated thyroid cancer; I-131; Radioactive iodine; High dose; Low dose

MeSH Terms

Follow-Up Studies
Iodine*
Thyroid Gland*
Thyroid Neoplasms*
Iodine
Full Text Links
  • NMMI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr